Literature DB >> 31375420

Intravenous Lidocaine for Chronic Neuropathic Pain A Systematic Review Addressing Nursing Care.

Rachelle J Lancaster1, Kathleen Wren2, Amy Hudson3, Karen Leavitt3, Maurizio Albala3, Dawn Tischaefer3.   

Abstract

BACKGROUND: The intravenous administration of lidocaine for patients with chronic neuropathic pain is well documented in the literature. However, little is known about the role of the nurse caring for patients receiving the infusion. AIM: The purpose of this systematic review was to examine and describe common side effects associated with the intravenous administration of lidocaine to patients with chronic neuropathic pain and outline nursing care described in an effort to develop evidence-based protocols for care.
METHOD: A comprehensive search of databases was completed and yielded eleven (n = 11) articles and one care protocol for analysis.
RESULTS: Evidence was appraised and findings suggest intravenous lidocaine has a low risk of causing adverse events, however patients should be monitored closely.
CONCLUSIONS: Nursing care focuses on pain assessment, close observation and intervention if neurological changes occur.
Copyright © 2019 American Society for Pain Management Nursing. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31375420     DOI: 10.1016/j.pmn.2019.06.008

Source DB:  PubMed          Journal:  Pain Manag Nurs        ISSN: 1524-9042            Impact factor:   1.929


  2 in total

1.  Lidocaine attenuates hypoxia/reoxygenation‑induced inflammation, apoptosis and ferroptosis in lung epithelial cells by regulating the p38 MAPK pathway.

Authors:  Xiaojun Ma; Weihua Yan; Na He
Journal:  Mol Med Rep       Date:  2022-03-04       Impact factor: 2.952

2.  Lidocaine inhibits the proliferation and migration of endometrial cancer cells, and promotes apoptosis by inducing autophagy.

Authors:  Dingde Long; Yayu Chen; Liangchao Qu; Yang Dong
Journal:  Oncol Lett       Date:  2022-08-17       Impact factor: 3.111

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.